The use of Fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma

• Published in: American journal of clinical oncology Vol. 36; no. 5; p. 472
• Main Authors: Peled, Yoav, Levavi, Hanoch, Krissi, Haim, Weill, Yehudah, Sabah, Gad, Eitan, Ram
• Format: Journal Article
• Language: English
• Published: United States 01.10.2013
• Subjects: Adenocarcinoma, Mucinous - drug therapy; Adenocarcinoma, Mucinous - mortality; Adenocarcinoma, Mucinous - pathology; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma, Papillary - drug therapy; Carcinoma, Papillary - mortality; Carcinoma, Papillary - pathology; Cystadenocarcinoma, Serous - drug therapy; Cystadenocarcinoma, Serous - mortality; Cystadenocarcinoma, Serous - pathology; Endometrial Neoplasms - drug therapy; Endometrial Neoplasms - mortality; Endometrial Neoplasms - pathology; Female; Fluorouracil - administration & dosage; Follow-Up Studies; Humans; Leucovorin - administration & dosage; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - mortality; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - mortality; Ovarian Neoplasms - pathology; Prognosis; Retrospective Studies; Survival Rate

Women suffering from recurrent platinum-resistant ovarian carcinoma go through several lines of chemotherapy, but eventually fail all conventional chemotherapy options. After failing multiple other regimens, we offer patients fluorouracil (5-FU) in a weekly regimen with leucovorin. For those women w...